Moderna shares surge on NIH national cancer vaccine initiative and Nasdaq-100 inclusion
The NIH's plan to make cancer vaccines a major research bet lifted Moderna and other mRNA biotech stocks sharply.
SuaraGarut.ID · +15 outlets
FDA approves Asahi Kasei's pritelivir (HOVILPRI) for refractory herpes infections
The approval covers mucocutaneous HSV lesions refractory or resistant to standard antivirals in immunocompromised adults.
Voice of Healthcare · +7 outlets
FDA approves Teva's Weltruza, first once-monthly subcutaneous olanzapine for schizophrenia
Weltruza offers a long-acting injectable alternative for adults with schizophrenia without added pills or post-shot monitoring.
Teva Pharmaceuticals · +14 outlets
FDA approves atezolizumab for stage III dMMR colon cancer after ATOMIC trial
The approval expands use of Roche's checkpoint inhibitor to earlier-stage mismatch repair deficient colon cancer.
Bioengineer.org · +14 outlets
FDA review documents spark Revolution Medicines sell-off over Rasonque KRAS data
Disclosure suggesting Rasonque may not be as broadly effective as thought pressured the biotech's shares.
Biopharmadive · +4 outlets
FDA withdraws Zepzelca approval for previously treated small cell lung cancer
The agency pulled the accelerated approval, removing a second-line option for SCLC patients.
Cure Today · +4 outlets
Pfizer's Tukysa approved for first-line HER2-positive breast cancer
The label expansion moves the drug into earlier treatment lines for HER2+ breast cancer.
Labroots · +14 outlets
FDA flags four deaths in Newron schizophrenia drug studies
A potential safety signal emerged after four patient deaths in a trial of the schizophrenia drug.
ETPharma.com · +6 outlets
Two former Moderna cancer vaccine scientists join Everest Medicines for US mRNA push
The hires aim to accelerate Everest's global clinical development of its mRNA pipeline.
Menafn · +4 outlets
Life Biosciences reports glaucoma patients dosed with cellular reprogramming drug
Three glaucoma patients received a single injection of the experimental reprogramming drug with no serious adverse events.
STAT · +14 outlets
Hospitals sue again to halt Trump administration's 340B rebate pilot
The AHA challenges a plan to convert a federal drug discount program from upfront discounts to after-the-fact rebates.
STAT · +10 outlets
China targets five billion-dollar innovative drugs by 2030 as biotech expands globally
The country aims to grow its biotech industry and global presence through a domestic drug-development push.
Sri Lanka Guardian · +14 outlets
STAT+: Steven Quay no longer in consideration for top NIAID infectious disease role
The biopharmaceutical executive with no infectious disease background was dropped from consideration for NIAID director.
STAT · +1 outlets
Survey finds Americans trust science more than peers in other nations
Just 40 percent of Americans reported a lot of confidence in US hospitals and health clinics, per the Wellcome survey.
STAT · +14 outlets
TRex Bio prices $117M IPO to support immune drug work
Eli Lilly is the largest equity holder in the Treg-focused autoimmune drug developer.
Biopharmadive · +2 outlets
FDA approves Parkinson's drug based on University of Virginia research
The approval advances a treatment developed from university-led research into Parkinson's disease.
FauquierNow · +14 outlets
US FDA rebuffs ITM's radiopharmaceutical for neuroendocrine tumors
The rejection delays the German radiopharma firm's lead product in the US market.
FirstWord Pharma · +1 outlets
Bowel cancer 'melted away' after immunotherapy and stayed in remission
A case report describes durable remission following immunotherapy in bowel cancer.
Science Daily · +1 outlets